Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
An announcement from CytomX Therapeutics ( (CTMX) ) is now available.
On January 30, 2025, CytomX Therapeutics announced the termination of employment for Jeffrey Landau, the Senior Vice President, Chief Business Officer, and Head of Strategy, effective February 7, 2025. The company has arranged a Separation Agreement that provides economic payments consistent with Mr. Landau’s prior severance agreement, and includes a general release of claims against the company.
More about CytomX Therapeutics
YTD Price Performance: -19.81%
Average Trading Volume: 1,299,665
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $66.52M
For an in-depth examination of CTMX stock, go to TipRanks’ Stock Analysis page.
